{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:23:10Z","timestamp":1782807790023,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jaad.2019.04.067","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T18:52:09Z","timestamp":1557600729000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["The human papillomavirus vaccine as a treatment for human papillomavirus\u2013related dysplastic and neoplastic conditions: A literature review"],"prefix":"10.1016","volume":"82","author":[{"given":"Christine T.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Juhasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin T.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Atanaskova","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcv.2012.07.014","article-title":"Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics","volume":"55","author":"Bruggink","year":"2012","journal-title":"J Clin Virol"},{"issue":"5","key":"10.1016\/j.jaad.2019.04.067_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/archdermatol.2010.71","article-title":"Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man","volume":"146","author":"Venugopal","year":"2010","journal-title":"Arch Dermatol"},{"issue":"343","key":"10.1016\/j.jaad.2019.04.067_bib5","doi-asserted-by":"crossref","first-page":"d4351","DOI":"10.1136\/bmj.d4351","article-title":"HPV vaccine may have role in wart treatment","volume":"12","author":"Martin","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jaad.2011.08.022","article-title":"Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine","volume":"67","author":"Landis","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2013.1463","article-title":"Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine","volume":"149","author":"Daniel","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3201\/eid2001.130999","article-title":"Resolution of novel human papillomavirus-induced warts after HPV vaccination","volume":"20","author":"Silling","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.jaad.2019.04.067_bib9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2340\/00015555-2111","article-title":"Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children","volume":"95","author":"Abeck","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib10","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamadermatol.2015.2805","article-title":"Effect of quadrivalent human papillomavirus vaccination on oral squamous cell papillomas","volume":"151","author":"Cyrus","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/bjd.13707","article-title":"Identification of the skin virome in a boy with widespread human papillomavirus-2-positive warts that completely regressed after administration of tetravalent human papillomavirus vaccine","volume":"173","author":"Landini","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.04.067_bib12","first-page":"533","article-title":"Spontaneous Remission of recalcitrant warts in girls after human papillomavirus vaccination","volume":"107","author":"Martin","year":"2016","journal-title":"Acta Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.jaad.2019.04.067_bib13","first-page":"367","article-title":"Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult","volume":"3","author":"Ferguson","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.13038","article-title":"Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine","volume":"42","author":"Smith","year":"2017","journal-title":"Clin Exper Dermatol"},{"key":"10.1016\/j.jaad.2019.04.067_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2017.11.022","article-title":"Spontaneous regression of a recalcitrant wart after bivalent papillomavirus vaccination","volume":"194","author":"Martin","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2019.04.067_bib16","first-page":"1","article-title":"Quadrivalent human papilloma virus vaccien for treatment of multiple warts: a retrospective analysis of 30 patients","volume":"20","author":"Yang","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200721010-00006","article-title":"MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I\/II study","volume":"21","author":"Albarran","year":"2007","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.jaad.2019.04.067_bib19","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.jaad.2010.12.032","article-title":"Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18)","volume":"64","author":"Lee","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2011.11.970","article-title":"Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients","volume":"68","author":"Kreuter","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.jaad.2019.04.067_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archdermatol.2010.290","article-title":"Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination","volume":"146","author":"Kreuter","year":"2010","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.04.067_bib23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jdv.13133","article-title":"Dual response to human papilloma virus vaccine in an immunodeficiency disorder: resolution of plantar warts and persistence of condylomas","volume":"30","author":"Moscato","year":"2016","journal-title":"J Eurn Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2019.04.067_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamadermatol.2016.5703","article-title":"Association of human papillomavirus vaccine with the development of keratinocyte carcinomas","volume":"153","author":"Nichols","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.04.067_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamadermatol.2018.1748","article-title":"Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas","volume":"154","author":"Nichols","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.04.067_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/000348940511400913","article-title":"HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial","volume":"114","author":"Derkay","year":"2005","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib27","first-page":"175","article-title":"Adjuvant therapy for laryngeal papillomatosis","volume":"20","author":"Boltezar","year":"2011","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"5","key":"10.1016\/j.jaad.2019.04.067_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/adc.2010.198184","article-title":"Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination","volume":"96","author":"Mudry","year":"2011","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.jaad.2019.04.067_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00405-013-2755-y","article-title":"Clinical efficiency of quadrivalent HPV (types 6\/11\/16\/18) vaccine in patients with recurrent respiratory papillomatosis","volume":"271","author":"Chirila","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijporl.2014.11.022","article-title":"Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine","volume":"79","author":"Meszner","year":"2015","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijporl.2013.12.013","article-title":"Prolonged remission of juvenile-onset respiratory papillomatosis: a post-expositional role of the tetravalent anti-HPV vaccine?","volume":"78","author":"Yi","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jvoice.2014.08.003","article-title":"The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma","volume":"29","author":"Young","year":"2015","journal-title":"J Voice"},{"key":"10.1016\/j.jaad.2019.04.067_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijporl.2016.10.032","article-title":"Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: a case report","volume":"91","author":"Baumanis","year":"2017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.jaad.2019.04.067_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijporl.2016.01.032","article-title":"Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory\u00a0papillomatosis","volume":"83","author":"Hermann","year":"2016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"19","key":"10.1016\/j.jaad.2019.04.067_bib35","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00405-016-4085-3","article-title":"Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis","volume":"273","author":"Tjon Pian Gi","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"10","key":"10.1016\/j.jaad.2019.04.067_bib36","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/lary.26580","article-title":"Nasopharyngeal papillomas treated with CO2 laser and human papillomavirus vaccination","volume":"127","author":"Cai","year":"2017","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jvoice.2016.01.008","article-title":"Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer","volume":"31","author":"Makiyama","year":"2017","journal-title":"J Voice"},{"key":"10.1016\/j.jaad.2019.04.067_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijporl.2016.12.035","article-title":"Therapeutic use of the HPV vaccine in recurrent respiratory papillomatosis: a case report","volume":"93","author":"Sullivan","year":"2017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.jaad.2019.04.067_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jvoice.2017.07.017","article-title":"Gardasil vaccination for recurrent laryngeal papillomatosis in adult men second report: negative conversion of HPV in laryngeal secretions","volume":"32","author":"Hirai","year":"2018","journal-title":"J Voice"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jvoice.2017.12.002","article-title":"Safety and immunogenicity of a nonadjuvant human papillomavirus type 6 virus-like particle vaccine in recurrent respiratory papillomatosis","volume":"33","author":"Zhang","year":"2019","journal-title":"J Voice"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib41","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s00405-014-3143-y","article-title":"Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis","volume":"271","author":"Ho\u010devar-Bolte\u017ear","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.jaad.2019.04.067_bib42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lio2.80","article-title":"Recurrent respiratory papillomatosis (RRP)-time for a reckoning?","volume":"2","author":"Kin Cho Goon","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2019.04.067_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00106-017-0378-0","article-title":"Treatment outcomes of recurrent respiratory papillomatosis: retrospective analysis of juvenile and adult cases","volume":"66","author":"Papaioannou","year":"2018","journal-title":"HNO"},{"issue":"4","key":"10.1016\/j.jaad.2019.04.067_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jpids\/pix063","article-title":"Treatment with quadrivalent human papillomavirus vaccine for juvenile-onset recurrent respiratory papillomatosis: case report and review of the literature","volume":"6","author":"Katsuta","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"9014","key":"10.1016\/j.jaad.2019.04.067_bib45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaad.2019.04.067_bib46","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib47","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2019.04.067_bib48","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2019.04.067_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib51","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2009.05.044","article-title":"Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia","volume":"116","author":"Van Doorslaer","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2019.04.067_bib52","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-012-1292-7","article-title":"A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions","volume":"61","author":"de Vos van Steenwijk","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"47","key":"10.1016\/j.jaad.2019.04.067_bib53","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","article-title":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2019.04.067_bib54","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"issue":"10008","key":"10.1016\/j.jaad.2019.04.067_bib55","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jaad.2019.04.067_bib57","doi-asserted-by":"crossref","first-page":"212.e211","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jaad.2019.04.067_bib58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/QAI.0b013e3181b7354c","article-title":"A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus","volume":"52","author":"Anderson","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"10.1016\/j.jaad.2019.04.067_bib60","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.jaad.2019.04.067_bib61","first-page":"6032","article-title":"Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins","volume":"63","author":"Davidson","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jaad.2019.04.067_bib62","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.jaad.2019.04.067_bib63","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2019.04.067_bib64","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2019.04.067_bib65","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-00009577-200605000-00020","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jaad.2019.04.067_bib66","doi-asserted-by":"crossref","first-page":"c2986","DOI":"10.1136\/bmj.c2986","article-title":"Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study","volume":"341","author":"Karagas","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jaad.2019.04.067_bib67","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnci\/djj092","article-title":"Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin","volume":"98","author":"Karagas","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2019.04.067_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1423-0127-17-32","article-title":"Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination","volume":"17","author":"Chuang","year":"2010","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.jaad.2019.04.067_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/TCRM.S856","article-title":"A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil)","volume":"4","author":"Govan","year":"2008","journal-title":"Ther Clin Risk Manag"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219307145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219307145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:12Z","timestamp":1759272732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219307145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0190962219307145"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.04.067","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The human papillomavirus vaccine as a treatment for human papillomavirus\u2013related dysplastic and neoplastic conditions: A literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}